Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Plans Further Audits Of Telavancin Study Sites; No Major Problems To Date

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm says FDA and company audits of telavancin clinical trial data are progressing well; no predictions on how long process may take.

You may also be interested in...



Burned By Ketek, FDA Took Care With Possible Data Integrity Issues For Telavancin

Congressional investigations into FDA's handling of data integrity issues with a safety trial for Sanofi-Aventis' antibiotic Ketek caught Theravance's pending antibiotic Vibativ (telavancin) in its wake, FDA review documents reveal

Burned By Ketek, FDA Took Care With Possible Data Integrity Issues For Telavancin

Congressional investigations into FDA's handling of data integrity issues with a safety trial for Sanofi-Aventis' antibiotic Ketek caught Theravance's pending antibiotic Vibativ (telavancin) in its wake, FDA review documents reveal

Theravance’s Telavancin Data Integrity Issues Resolved; FDA Review Back On Track

FDA will resume the review of Theravance’s antibiotic telavancin at a three-day advisory committee meeting in November after completing an audit of the company’s clinical trial data.

Related Content

Topics

UsernamePublicRestriction

Register

PS068141

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel